ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,472,196, issued on Nov. 18, was assigned to Ohara Pharmaceutical Co. Ltd. (Koka, Japan) and Saga University (Saga, Japan).
"Use of DNMT inhibitor" was invented by Magoichi Sako (Koka, Japan), Yuki Kurahashi (Koka, Japan), Shinya Kimura (Saga, Japan), Tatsuro Watanabe (Saga, Japan), Hiroshi Ureshino (Saga, Japan) and Kazuharu Kamachi (Saga, Japan).
According to the abstract* released by the U.S. Patent & Trademark Office: "[Problems] The object is to provide a compound as a therapeutic or prophylactic agent for TKI-resistant CML to replace the injection "Dacogen(R)" which has been clinically used as a therapeutic agent for high-risk myelodysplastic syndrome and acute myeloid leukemia....